IDEAS home Printed from https://ideas.repec.org/a/spr/drugsa/v39y2016i3d10.1007_s40264-015-0381-x.html
   My bibliography  Save this article

Clinicians’ Reports in Electronic Health Records Versus Patients’ Concerns in Social Media: A Pilot Study of Adverse Drug Reactions of Aspirin and Atorvastatin

Author

Listed:
  • Maxim Topaz

    (Brigham and Women’s Hospital
    Harvard Medical School)

  • Kenneth Lai

    (Partners HealthCare System)

  • Neil Dhopeshwarkar

    (Brigham and Women’s Hospital)

  • Diane L. Seger

    (Brigham and Women’s Hospital
    Partners HealthCare System)

  • Roee Sa’adon

    (Treato Ltd.)

  • Foster Goss

    (University of Colorado)

  • Ronen Rozenblum

    (Brigham and Women’s Hospital
    Harvard Medical School)

  • Li Zhou

    (Brigham and Women’s Hospital
    Harvard Medical School
    Partners HealthCare System)

Abstract

Introduction Large databases of clinician reported (e.g., allergy repositories) and patient reported (e.g., social media) adverse drug reactions (ADRs) exist; however, whether patients and clinicians report the same concerns is not clear. Objectives Our objective was to compare electronic health record data and social media data to better understand differences and similarities between clinician-reported ADRs and patients’ concerns regarding aspirin and atorvastatin. Methods This pilot study explored a large repository of electronic health record data and social media data for clinician-reported ADRs and patients concerns for two common medications: aspirin (n = 31,817 ADRs accessible in clinical data; n = 19,186 potential ADRs accessible in social media data) and atorvastatin (n = 15,047 ADRs accessible in clinical data; n = 23,408 potential ADRs accessible in social media data). Results We found that the most frequently reported ADRs matched the most frequent patients’ concerns. However, several less frequently reported reactions were more prevalent on social media (i.e., aspirin-induced hypoglycemia was discussed only on social media). Overall, we found a relatively strong positive and statistically significant correlation between the frequency ranking of reactions and patients’ concerns for atorvastatin (Pearson’s r = 0.61, p

Suggested Citation

  • Maxim Topaz & Kenneth Lai & Neil Dhopeshwarkar & Diane L. Seger & Roee Sa’adon & Foster Goss & Ronen Rozenblum & Li Zhou, 2016. "Clinicians’ Reports in Electronic Health Records Versus Patients’ Concerns in Social Media: A Pilot Study of Adverse Drug Reactions of Aspirin and Atorvastatin," Drug Safety, Springer, vol. 39(3), pages 241-250, March.
    • Handle: RePEc:spr:drugsa:v:39:y:2016:i:3:d:10.1007_s40264-015-0381-x
    DOI: 10.1007/s40264-015-0381-x
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40264-015-0381-x
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40264-015-0381-x?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Lucie M. Gattepaille & Sara Hedfors Vidlin & Tomas Bergvall & Carrie E. Pierce & Johan Ellenius, 2020. "Prospective Evaluation of Adverse Event Recognition Systems in Twitter: Results from the Web-RADR Project," Drug Safety, Springer, vol. 43(8), pages 797-808, August.
    2. Sabine Brosch & Anne-Marie Ferran & Victoria Newbould & Diane Farkas & Marina Lengsavath & Phil Tregunno, 2019. "Establishing a Framework for the Use of Social Media in Pharmacovigilance in Europe," Drug Safety, Springer, vol. 42(8), pages 921-930, August.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:39:y:2016:i:3:d:10.1007_s40264-015-0381-x. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.